"Super Vaccine" technology projected to produce 34,900% revenue surge within 1 year

This is big (and underreported) You are receiving this as part of your subscription to Cannabis Profits Daily. To remove your email from this list, [unsubscribe here](. [Cannabis Profits Daily]( Pfizer Just Made a Major Vaccine Announcement... But Our Intel Shows [This Company]( Still Beats Them to Market Dear Cannabis Profits Daily Reader, I'm sure you've seen the news by now. Pfizer, one of the largest biotech companies in the world, reported 90% effectiveness from their COVID-19 vaccine after completing their Phase III trial. It's perfect timing because demand for a vaccine is through the roof. So no wonder Pfizer stock moved 14% within minutes. But let me be clear... This race is NOT over. Pfizer's vaccine has a long road ahead before it hits the market. Which means [tiny biotechs like this one]( are very much still in the running. And unlike $200 billion companies like Pfizer, these tiny stocks have the potential to absolutely skyrocket on positive news. Consider the company we just recommended - the one with what we call a "[Super Vaccine]( in the pipeline. Our team is projecting an unprecedented 34,900% revenue surge within the next 12 months. It's possible because, again, this company is tiny - 73X smaller than Pfizer. Which is probably why, despite their own incredible viable vaccine developments, [this panel of genius scientists]( has remained under the radar. But they won't for long... Because they plan to make a MAJOR announcement before the end of November. ([Details here]( Once that happens, we could all see their "Super Vaccine" front and center, which could easily trigger [the 34,900% revenue surge we're projecting within the next 12 months](. In order to capitalize on this opportunity, you'll need to act quickly. This company's announcement is just days away, which means time is limited to secure a position before the stock skyrockets. [Click here to see all the details](. Sincerely, Bob Keppel Publisher, Cannabis Profits Daily [National Institute for Cannabis Investors] Please do not reply to this email. It was sent from an unmonitored mailbox. You are receiving this e-mail at {EMAIL}, as part of your subscription to Cannabis Profits Daily. To remove your email from this list: [unsubscribe here](. To cancel, or for any other questions or requests, please contact our Customer Service team: [Online]( Phone: 866-260-0361 (North America) 410-777-8270 (International) Mail: Cannabis Profits Daily | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 Our Customer Service team is available Monday ‑ Friday between 9:00 AM and 5:00 PM ET. © 2020 The National Institute for Cannabis Investors. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: The National Institute for Cannabis Investors. 1125 N Charles Street, Baltimore, MD 21201. [Website]( | [Privacy Policy]( | [Terms & Conditions](